{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:22:10Z","timestamp":1763400130269,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Study of clinical characteristics of hepatitis B virus deoxyribonucleic acid (HBV DNA)-negative, hepatitis B surface antigen (HBsAg)-positive, hepatitis B e antigen (HBeAg)-negative patients based on liver histopathology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively enrolled patients with chronic HBV infection diagnosis at Beijing Ditan Hospital from May 2008 to November 2020. To study the differences between patients with significant hepatic histopathology and those without significant hepatic histopathology. And to study the independent factors of significant hepatic histopathology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>85 HBV DNA-negative and HBeAg-negative patients were 37.90 \u00b1 10.30 years old, 23.50% of patients with grade of inflammation (G) &amp;gt;1, 35.30% of patients with liver fibrosis stage (S) &amp;gt;1, 44.70% patients were diagnosed with significant hepatic histopathology. Compared to the no significant hepatic histopathology group, another group had older age (41.70 \u00b1 10.70 vs 34.80 \u00b1 8.87 years, t=-3.28, <jats:italic>P<\/jats:italic>=0.002), higher total bilirubin (TBIL) [14.9(10.3, 22.4) vs 11(8.9, 14.4) \u03bcmol\/L, z=-2.26, <jats:italic>P<\/jats:italic>=0.024], lower cholinesterase (CHE) (t=-2.86, <jats:italic>P<\/jats:italic>=0.005, 7388.00 \u00b1 2156.00 vs 8988.00 \u00b1 2823.00 U\/L) and lower platelet (PLT) (t=2.75, <jats:italic>P<\/jats:italic>=0.007, 157.00 \u00b1 61.40 vs 194.00 \u00b1 61.00 10^9\/L). Abnormal ALT patients are more likely to have significant hepatic histopathology (z=5.44, <jats:italic>P<\/jats:italic>=0.020, 66.70% vs 337.50%). G had significant correlation with CHE (<jats:italic>P<\/jats:italic>=0.008, r=-0.23), alanine aminotransferase (ALT) (<jats:italic>P<\/jats:italic>=0.041, r=0.18), aspartate aminotransferase (AST) (<jats:italic>P<\/jats:italic>=0.001, r=0.29). S had significant correlation with TBIL (<jats:italic>P<\/jats:italic> = 0.008, r = 0.23), age (<jats:italic>P<\/jats:italic> &amp;lt; 0.001, r = 0.32), international normalized ratio (INR) (<jats:italic>P<\/jats:italic> = 0.04, r = 0.23), CHE (<jats:italic>P<\/jats:italic> &amp;lt; 0.001, r = -0.30), PLT (<jats:italic>P<\/jats:italic> &amp;lt; 0.001, r = -0.40) and prothrombin time activity (PTA) (<jats:italic>P<\/jats:italic> = 0.046, r = -0.22). Multivariate logistic analysis indicated only age (95%CI=1.014~1.130, OR=1.069, <jats:italic>P<\/jats:italic>=0.013) was an impact factor for significant hepatic histopathology. The cutoff point of age was 34.30 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A large proportion of chronic HBV infection patients with HBeAg-negative and HBV DNA-negative still have chronic hepatitis. Age is an independent factor for significant hepatic histopathology<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1113070","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T18:22:37Z","timestamp":1672942957000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxiao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leiping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis b virus infection eligible for hepatitis b antiviral treatment worldwide: a systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/v13030368","article-title":"HBV-integration studies in the clinic: Role in the natural history of infection","volume":"13","author":"Pollicino","year":"2021","journal-title":"Viruses"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address e e e, European association for the study of the L.EASL 2017 clinical practice guidelines on the management of hepatitis b virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s12072-021-10137-2","article-title":"Chronic hepatitis b: the demise of the 'inactive carrier' phase","volume":"15","author":"Koffas","year":"2021","journal-title":"Hepatol Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jhep.2011.11.030","article-title":"Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis b virus infection with persistently normal ALT: a systematic review","volume":"57","author":"Papatheodoridis","year":"2012","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis b virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2020.11.003","article-title":"Transition to HBeAg-negative chronic hepatitis b virus infection is associated with reduced cccDNA transcriptional activity","volume":"74","author":"Suslov","year":"2021","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis b","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis b","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-007-9002-9","article-title":"Spontaneous relapse of hepatitis in inactive HBsAg carriers","volume":"1","author":"Chu","year":"2007","journal-title":"Hepatol Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.08.010","article-title":"Prediction of disease reactivation in asymptomatic hepatitis b e antigen-negative chronic hepatitis b patients using baseline serum measurements of HBsAg and HBV-DNA","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J Clin Virol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1478-3231.2011.02693.x","article-title":"Predictive value of HBsAg quantification for determining the clinical course of genotype c HBeAg-negative carriers","volume":"32","author":"Park","year":"2012","journal-title":"Liver Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis b surface antigen serum levels help to distinguish active from inactive hepatitis b virus genotype d carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13416","article-title":"Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis b virus infection: Benign course towards HBsAg clearance","volume":"37","author":"Oliveri","year":"2017","journal-title":"Liver Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16258","article-title":"Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis","volume":"53","author":"Brunetto","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/16.5.709","article-title":"Sex difference in chronic hepatitis b virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers","volume":"16","author":"Chu","year":"1993","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/ijms23031552","article-title":"Hepatitis b flare in hepatitis b e antigen-negative patients: A complicated cascade of innate and adaptive immune responses","volume":"23","author":"Chang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis b surface antigen and long-term clinical outcomes of patients with chronic hepatitis b virus infection: Systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.893512","article-title":"Immune mechanisms underlying hepatitis b surface antigen seroclearance in chronic hepatitis b patients with viral coinfection","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.virs.2022.03.001","article-title":"Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis b patients","volume":"37","author":"Li","year":"2022","journal-title":"Virol Sin"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-020-00290-7","article-title":"Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis b after treatment with pegylated interferonalpha-2a","volume":"36","author":"Li","year":"2021","journal-title":"Virol Sin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.960589","article-title":"An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis b patients","volume":"13","author":"Li","year":"2022","journal-title":"Front Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1113070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T18:22:40Z","timestamp":1672942960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1113070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2022.1113070"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1113070","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"article-number":"1113070"}}